news
FDA Advisory Committee votes on investigational medicine metreleptin
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
List view / Grid view
AstraZeneca
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news
FDA advisory committee recommends the investigational SGLT2 inhibitor dapagliflozin for treatment of type 2 diabetes in adults
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
news
AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
news
AstraZeneca awarded damages in Prilosec® patent litigation
4 December 2013 | By AstraZeneca
AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc...
news
Xigduo™ receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
news
AstraZeneca appoints architect for new global R&D centre and corporate headquarters in Cambridge, UK
19 November 2013 | By AstraZeneca
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre...
news
New Drug Application for naloxegol accepted by United States Food and Drug Administration
19 November 2013 | By AstraZeneca
The NDA filing was based on comprehensive data from the core Phase III KODIAC programme...
news
AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex in Macclesfield
11 November 2013 | By AstraZeneca
Zoladex has been manufactured at AstraZeneca’s Macclesfield plant for over 25 years, supplying the medicine to more than one hundred markets around the world...
news
Marc Dunoyer appointed Chief Financial Officer of AstraZeneca
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
news
AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
article
Omega-3 to the rescue
28 October 2013 | By Dr Kevin Robinson
End-users, be they patients or consumers, are taking a good look at the cardiovascular benefits of omega-3s … and tend to like what they see.
news
AstraZeneca announces proposal to close Brixham Environmental Laboratory
24 October 2013 | By AstraZeneca
The proposal to close the site has been made as the work undertaken at the laboratory is outside the organisation’s strategic focus...
news
AstraZeneca initiates phase III clinical programme for selumetinib, a treatment in development for patients with non-small-cell lung cancer
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
news
OGT strengthens focus on cancer biomarkers with appointment of Dr Bob Holland as CMO
21 October 2013 | By College Hill
Dr Holland is an expert in biomarker-driven drug development...
news
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
